Drug development

Microneedle Flu Vaccine Market Research 2024 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - ResearchAndMarkets.com

Retrieved on: 
금요일, 5월 3, 2024
Pharmaceutical, Health, Medical Supplies, USD, Mortality, Public, Vaccination, Pandemic, Fear, Influenza, Risk, Measles, Skin, Infection, Iontophoresis, Research, Sonophoresis, Vaccine, Disease, Patient, Marketing, Season, Drug development, Anxiety, Viral, COVID-19, Injection

The "Microneedle Flu Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microneedle Flu Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F" report has been added to ResearchAndMarkets.com's offering.
  • Global Microneedle Flu Vaccine Market was valued at USD 1.10 Billion in 2023 and is anticipated to grow with a CAGR of 5.89% through 2029.
  • Expanding the vaccine portfolio beyond seasonal influenza vaccines opens up new revenue streams for manufacturers and developers in the microneedle vaccine market.
  • Based on the Vaccine Type segment, the Trivalent Flu Vaccine segment has been the dominant force in the market.

Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment

Retrieved on: 
목요일, 5월 2, 2024
Surgery, Science, Other Health, Veterinary, Nursing, Medical Supplies, Radiology, FDA, Other Science, Pharmaceutical, Diabetes, Research, Optical, Oncology, Mental Health, Medical Devices, Stem Cells, Infectious Diseases, Health Technology, Practice Management, Hospitals, Physical Therapy, Genetics, Managed Care, Fitness & Nutrition, Dental, Clinical Trials, Cardiology, Biotechnology, Alternative Medicine, AIDS, Health, Immunoglobulin G, Automation, ADAS, Safety, Pharmacokinetics, Animal, Primate, Software, Therapy, Litre, Toxicokinetics, Drug development

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® Generic Rodent Anti-Drug Antibody (ADA) Kit Reagents for the detection of circulating immune complexes of human IgG with rodent anti-human IgG.

Key Points: 
  • Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® Generic Rodent Anti-Drug Antibody (ADA) Kit Reagents for the detection of circulating immune complexes of human IgG with rodent anti-human IgG.
  • The Gyrolab Generic Rodent ADA Kit fills an industry-wide need for a generic assay solution to expedite immunogenicity assessment.
  • Following the introduction of Gyrolab Generic Cyno ADA Kit Reagents, the Gyrolab Generic Rodent ADA Kit Reagents further expand the utility of the Gyrolab platform into earlier drug screening and preclinical phases of development.
  • Mark Vossenaar, General Manager, Biopharmaceutical Development Division, Gyros Protein Technologies, commented: “The addition of the Gyrolab Generic Rodent ADA Kit Reagents to our portfolio enhances our offering of ready-to-use kits and solutions for use in drug screening and preclinical development.

Allucent Recognized with CRO Leadership Awards for Expertise and Compatibility

Retrieved on: 
목요일, 5월 2, 2024
ChromeOS, Expert, Compatibility, Drug development, Industry Standard, Partnership, ISR, Research, Fine chemical

CARY, N.C., May 2, 2024 /PRNewswire/ -- Allucent , a global mid-sized clinical research organization (CRO), received two CRO Leadership Awards presented by Clinical Leader and Life Science Connect for the second consecutive year.

Key Points: 
  • CARY, N.C., May 2, 2024 /PRNewswire/ -- Allucent , a global mid-sized clinical research organization (CRO), received two CRO Leadership Awards presented by Clinical Leader and Life Science Connect for the second consecutive year.
  • Recipients of these awards are determined based on research conducted by Industry Standard Research (ISR) to identify CROs that meet or exceed their customers' expectations.
  • This year, Allucent received awards in the Expertise and Compatibility categories across Small Pharma and Overall (Big and Small Pharma combined).
  • "We're honored to be recognized through the CRO Leadership Awards for the second consecutive year," said Mark A. Goldberg, M.D., chairman and chief executive officer of Allucent.

AI In Life Science Analytics Market worth $3.56 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on: 
목요일, 5월 2, 2024
Report, Genomics, Investment, AI, Health, Proteomics, Partnership, Research, Artificial intelligence, Growth, Health information management, Physician, Face, Drug development, Medicine, COVID-19, IBM, Incredible, Medical device

Incredible possibilities for pattern discovery, disease outcome prediction, and optimization of healthcare and life sciences research await in the mountains of data.

Key Points: 
  • Incredible possibilities for pattern discovery, disease outcome prediction, and optimization of healthcare and life sciences research await in the mountains of data.
  • Utilizing AI, researchers, healthcare experts, and pharmaceutical businesses can easily integrate and analyze various forms of data, which in turn allows them to uncover useful insights.
  • The North American AI in life science analytics market is anticipated to record a large market share in terms of revenue.
  • In Dec 2022, Quantori formed a partnership with Databricks to expedite data-driven advancements in the fields of life sciences and healthcare.

AI In Life Science Analytics Market worth $3.56 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on: 
목요일, 5월 2, 2024
Report, Genomics, Investment, AI, Health, Proteomics, Partnership, Research, Artificial intelligence, Growth, Health information management, Physician, Face, Drug development, Medicine, COVID-19, IBM, Incredible, Medical device

Incredible possibilities for pattern discovery, disease outcome prediction, and optimization of healthcare and life sciences research await in the mountains of data.

Key Points: 
  • Incredible possibilities for pattern discovery, disease outcome prediction, and optimization of healthcare and life sciences research await in the mountains of data.
  • Utilizing AI, researchers, healthcare experts, and pharmaceutical businesses can easily integrate and analyze various forms of data, which in turn allows them to uncover useful insights.
  • The North American AI in life science analytics market is anticipated to record a large market share in terms of revenue.
  • In Dec 2022, Quantori formed a partnership with Databricks to expedite data-driven advancements in the fields of life sciences and healthcare.

The Galien Foundation's Prix Galien UK Forum Returns to London in May 2024

Retrieved on: 
목요일, 5월 2, 2024
Science Museum, FDA, University, NHS, Lazard, Forum, Food and Drug Administration, Gilead Sciences, Drug development, Food, Heart, Data science, Isomorphic Labs, Science, CDER, Natural History Museum, Intelligence, Awards ceremony, Patient, Access, Global health, NHS England, University of Edinburgh, Pharmaceutical industry

The Prix Galien UK Forum brings together industry scientists, researchers, and organisations at the forefront of scientific advancement to exchange and offer perspectives on the future of global health.

Key Points: 
  • The Prix Galien UK Forum brings together industry scientists, researchers, and organisations at the forefront of scientific advancement to exchange and offer perspectives on the future of global health.
  • Together with the evening Prix Galien Awards Ceremony recognising the best in UK medicine, the events reflect the worldwide mission of The Galien Foundation to improve the human condition through breakthrough innovations that progress the understanding in diagnosing, treating, and curing disease.
  • Following the Prix Galien UK Forum, the Prix Galien UK Awards Ceremony will take place at the Natural History Museum, London, from 7:30 PM – 10:30 PM.
  • To learn more about the 2024 Prix Galien Forum and Awards Ceremony, please visit: https://prixgalien.co.uk/ .

Global Functional Dyspepsia Drug Market to reach a valuation of US$ 16.4 billion by 2034, Future Market Insights, Inc. Projection

Retrieved on: 
수요일, 5월 1, 2024
Gastroenterology, Transplant, Acupuncture, Indigestion, Research, Laboratory, Probiotic, Abbott Laboratories, Herbal, Therapy, Patient, Tissue engineering, Enzyme inhibitor, Regenerative medicine, Collaboration, Market, Diagnosis, Antacid, Drug development, Regeneration, Ageing, Investment, Nutritional science, Pharmaceutical industry

NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population. The trend is set to create new opportunities for the market, leading to a projected CAGR of 4.8% between 2024 and 2034, and reaching a total valuation of approximately US$ 16.4 billion by 2034.

Key Points: 
  • NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population.
  • Collaboration between pharmaceutical companies, academic institutions, and research organizations fosters innovation in functional dyspepsia drug development.
  • Key Takeaways from the Market Study:
    Global functional dyspepsia drug market was valued at US$ 9.7 billion in 2023.
  • The functional dyspepsia drug market is characterized by a diverse array of pharmaceutical companies, research institutions, and healthcare organizations striving to develop and commercialize innovative treatments for functional dyspepsia.

Global Functional Dyspepsia Drug Market to reach a valuation of US$ 16.4 billion by 2034, Future Market Insights, Inc. Projection

Retrieved on: 
수요일, 5월 1, 2024
Gastroenterology, Transplant, Acupuncture, Indigestion, Research, Laboratory, Probiotic, Abbott Laboratories, Herbal, Therapy, Patient, Tissue engineering, Enzyme inhibitor, Regenerative medicine, Collaboration, Market, Diagnosis, Antacid, Drug development, Regeneration, Ageing, Investment, Nutritional science, Pharmaceutical industry

NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population. The trend is set to create new opportunities for the market, leading to a projected CAGR of 4.8% between 2024 and 2034, and reaching a total valuation of approximately US$ 16.4 billion by 2034.

Key Points: 
  • NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population.
  • Collaboration between pharmaceutical companies, academic institutions, and research organizations fosters innovation in functional dyspepsia drug development.
  • Key Takeaways from the Market Study:
    Global functional dyspepsia drug market was valued at US$ 9.7 billion in 2023.
  • The functional dyspepsia drug market is characterized by a diverse array of pharmaceutical companies, research institutions, and healthcare organizations striving to develop and commercialize innovative treatments for functional dyspepsia.

Ellipses' next generation selective RET inhibitor EP0031/A400 cleared to start Phase 2

Retrieved on: 
수요일, 5월 1, 2024
FDA, Brain, Fast track (FDA), Drug development, Food, RET, ASCO, Patient, SRI, NSCLC, Pharmaceutical industry

LONDON, May 1, 2024 /PRNewswire/ -- Ellipses Pharma Limited ("Ellipses"), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today the U.S. Food and Drug Administration (FDA) has confirmed the company's next generation selective RET inhibitor (SRI), EP0031/A400, is clear to progress into Phase 2 clinical development.

Key Points: 
  • EP0031/A400 is a potential treatment of RET-altered tumours and clinical data in studies to date has shown promising efficacy in patients with NSCLC, thyroid and other solid tumours.
  • Durable responses have been seen in patients who were naive to, or who had been pre-treated with, 1st generation SRIs including in patients with brain metastases1.
  • The latest clinical data from the Ellipses Phase 1 study will be presented at ASCO in Chicago on June 3rd 2024.
  • Modular Phase 1 studies have been conducted in the US, Europe and China and a registrational Phase 2 trial in China is ongoing.

Ellipses' next generation selective RET inhibitor EP0031/A400 cleared to start Phase 2

Retrieved on: 
수요일, 5월 1, 2024
FDA, Brain, Fast track (FDA), Drug development, Food, RET, ASCO, Patient, SRI, NSCLC, Pharmaceutical industry

LONDON, May 1, 2024 /PRNewswire/ -- Ellipses Pharma Limited ("Ellipses"), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today the U.S. Food and Drug Administration (FDA) has confirmed the company's next generation selective RET inhibitor (SRI), EP0031/A400, is clear to progress into Phase 2 clinical development.

Key Points: 
  • EP0031/A400 is a potential treatment of RET-altered tumours and clinical data in studies to date has shown promising efficacy in patients with NSCLC, thyroid and other solid tumours.
  • Durable responses have been seen in patients who were naive to, or who had been pre-treated with, 1st generation SRIs including in patients with brain metastases1.
  • The latest clinical data from the Ellipses Phase 1 study will be presented at ASCO in Chicago on June 3rd 2024.
  • Modular Phase 1 studies have been conducted in the US, Europe and China and a registrational Phase 2 trial in China is ongoing.